Levodopa/carbidopa controlled release - Intec Pharma

Drug Profile

Levodopa/carbidopa controlled release - Intec Pharma

Alternative Names: Accordion Pill levodopa/carbidopa; AP 09004; AP-CD/LD; AP-CDLD; Carbidopa/levodopa - Intec; Levodopa/carbidopa gastric retentive; Levodopa/carbidopa GR; The Accordion Pill carbidopa/levodopa

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Intec Pharma
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Parkinson's disease

Most Recent Events

  • 19 Jul 2017 Intec Pharma receives patent allowance for Levodopa/carbidopa controlled release in Hong Kong
  • 24 May 2017 Intec Pharma receives patent allowance for Accordion Pill levodopa/carbidopa in USA
  • 29 Mar 2017 Intec Pharma initiates the phase III Accordance-OLE trial in Parkinson's disease (In the elderly, In adults)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top